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Role of galectin-3 as a receptor for advanced glycosylation end cations of the disease through several mechanisms [1].
products. The advanced glycosylation end product (AGE)- Both early sugar adducts (Amadori products) [2] and
binding proteins identified so far include the components of advanced glycation end products (AGEs) [3] accumulatethe AGE-receptor complex p60, p90 and galectin-3, receptor
within tissues of humans and animals with diabetes andfor advanced glycosylation end products (RAGE), and the
may induce injurious effects either directly [1] or throughmacrophage scavenger receptor types I and II. Galectin-3 inter-
acts with b-galactoside residues of several cell surface and structurally distinct cell surface receptors [3, 4]; further-
matrix glycoproteins through the carbohydrate recognition do- more, both early and advanced glycation reactions are
main and is also capable of peptide–peptide associations medi- associated with oxidative stress [5, 6].ated by its N-terminus domain. These structural properties
Among these mechanisms, the AGE/AGE-receptor-enable galectin-3 to exert multiple functions, including the
mediated pathway appears to play a pivotal role in modu-modulation of cell adhesion, the control of cell cycle, and the
mRNA splicing activity. Moreover, in macrophages, astrocytes, lating target tissue injury. In fact, this pathway is involved
and endothelial cells, galectin-3 has been shown to exhibit a in both the removal of irreversibly glycated molecules,
high-affinity binding for AGEs; the lack of a transmembrane which is a major mechanism for protecting tissues from
anchor sequence or signal peptide suggests that it associates
AGE-induced damage, and the activation of cell growthwith other AGE-receptor components rather than playing an
and secretory function, which results in a dysregulatedindependent role as AGE-receptor. In tissues that are targets
of diabetic vascular complications, such as the mesangium and process of tissue remodeling [3]. The altered remodeling
the endothelium, galectin-3 is not expressed or only weakly triggered by AGE binding to cell surface receptors is
expressed under basal conditions, at variance with p90 and characterized by enhanced deposition of extracellular
p60 but becomes detectable with aging and is induced or up-
matrix (ECM) [7, 8], as well as by altered cell growth andregulated by the diabetic milieu, which only slightly affects the
turnover [9]. These changes appear to be mediated byexpression of p90 or p60. This (over)expression of galectin-
3 may in turn modulate AGE-receptor-mediated events by an abnormal pattern of expression of several cytokines,
modifying the function of the AGE-receptor complex, which including the insulin-like growth factors [10], platelet-
could play a role in the pathogenesis of target tissue injury. derived growth factor [11], transforming growth factor-b
Up-regulated galectin-3 expression may also exert direct effects
(TGF-b) [12], and vascular endothelial growth factor [13],on tissue remodeling, independently of AGE ligands, by virtue
through the activation of signaling molecules such as theof its adhesive and growth regulating properties.
p21(ras)-dependent mitogen-activated protein kinase
(MAPK) [14] and its downstream targets and the tran-
scription factors, NF-kB and the AP-1 complex [13, 14].A large body of experimental evidence indicates that
AGE-receptors are heterogeneous, just as their ligandthe enhanced nonenzymatic glycation occurring in diabe-
AGEs. In fact, several AGE-binding proteins have beentes is implicated in the pathogenesis of long-term compli-
identified so far [15], including p60, a 50 kD protein homol-
ogous to a component of the oligosaccharyltransferase
1 Current address: Dr. F. Pricci, Laboratorio di Metabolismo e Biochim- complex OST-48 (AGE-R1) [16]; p90, a 80 kD protein
ica Patologica, Istituto Superiore di Sanita`, Rome, Italy. homologous to the PKC substrate 80K-H (AGE-R2) [16];
galectin-3, a 32 kD protein previously known as Mac-2Key words: nonenzymatic glycation, AGE-receptor, diabetic complica-
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Table 1. AGE-binding proteins
Protein MW Structural features Function
p60 (AGE-R1) 50 kD Homologous to the oligosaccharyl transferase complex OST-48 form a complex with AGE uptake and
DAD1 and ribophorin I and II in the endoplasmic reticulum degradation
p90 (AGE-R2) 80 kD Homologous to the PKC and FGFR3 substrate 80K-H when phosphorylated binds
the SH2 domain of Grb2 in a complex with Sos cell activation
Galectin-3 (AGE-R3) 32 kD Previously known as Mac-2 or carbohydrate-cell activation binding protein (CBP)-35
C-terminal CRD and N-terminal PGAY repeating domain cell activation
RAGE 35 kD Member of the Ig superfamily proteolytic fragment of a 45-kD protein forming cell activation
complex with lactoferrin-like protein oxidative stress
Scavenger receptor type I 220 kD Homotrimeric protein with five domains: N-terminal cytoplasmic, transmembrane, AGE uptake and
spacer of 2-N linked sites, collagen-like triple helix, C-terminal cysteine-rich degradation
Scavenger receptor type II 170 kD As scavenger receptor I except for the cysteine-rich domain, replaced by a 6-residue AGE uptake and
C-terminus degradation
Fig. 1. Structure of galectin-3. (Modified from
Barondes SH, Cooper DNW, Gitt MA, Leffler
H: Galectins. Structure and function of a large
family of animal lectins. J Biol Chem 269:
20807–20810, 1995)
superfamily of receptors [18]; and macrophage scavenger Galectin-3 interacts with the b-galactoside residues of
receptor type I and type II [19] (Table 1). Lactoferrin and several ECM and cell surface glycoproteins through the
lysozyme also exhibit heparin-and polyanion-inhibitable CRD. When bound to multivalent glycoconjugates, it is
AGE-binding activity [20]. also capable of peptide-peptide homodimeric and hetero-
This paper focuses on the multifunctional molecule dimeric associations [21, 22]. In the absence of its saccha-
galectin-3, the most recently identified AGE-receptor, ride ligands, galectin-3 also self-associates in a C-terminus-
with special attention to its AGE-receptor function and dependent and carbohydrate-inhibitable manner [23, 24].
relevance in the pathogenesis of long-term complications These structural properties enable galectin-3 to exert
of diabetes. multiple functions that make it a broad-spectrum bio-
logic response modifier [22].
In the human genome, galectin-3 is coded by a singleGALECTIN-3 PROTEIN STRUCTURE AND
gene, mapped to human chromosome 14 at regionGENE REGULATION
14q21–22 [25]. It is composed of six exons and five in-Galectin-3 belongs to the lectin family of adhesion mol-
trons, spanning a total of about 17 kb. Two transcriptionecules. Galectins are lactose/galactose-specific lectins (cat-
initiation sites are located upstream of the exon I–intron Iion-independent) as opposed to selectins (cation-depen-
border; the translation start site is located in exon II,dent) [21, 22]. Its structure consists of two domains, the
the N-terminal domain within exon III, and the CRDC-terminal carbohydrate recognition domain (CRD), with
within exon V [26].highly conserved residues between members of the fam-
ily, and the N-terminal domain, shared with galectin-4,
Galectin-3 cell distribution and external secretionwith a unique short end continuing into an intervening
Galectin-3 shows a ubiquitous localization within theproline-glycine-alanine-tyrosine-rich (PGAY) repeat mo-
tif (Fig. 1). cell, although it is localized mainly in the cytoplasm [27].
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However, a significant amount of this lectin can also be nuclear ligand for galectin-3 (and galectin-1) has not
been identified yet. Within the nucleus, galectin-3 anddetected in the nucleus, depending on the cell type and
proliferative state. The phosphorylated form is found galectin-1 colocalize in speckled structures with the Sm
epitopes of the small nuclear ribonucleoprotein com-both in the nucleus of proliferating cells and cytoplasm
of quiescent cells, whereas the nonphosphorylated form plexes (snRNPs) and the non-snRNP splicing factor
SC35, thus indicating a functional redundancy of nuclearlocalizes exclusively in the nucleus of proliferating cells
[28]. Moreover, serum-stimulated 3T3 fibroblasts show galectins in their splicing activity and partitioning in the
nucleoplasm with other splicing factors [34]. Within thehigher levels of galectin-3 than quiescent cells in culture
[28, 29]. The expression (and localization) of galectin-3 nucleus, galectin-3 is also associated with single-stranded
DNA (ssDNA) and RNA, with the highest affinity foralso varies according to the replicative capacity of the
cell, decreasing with aging in association with loss of poly(A) ribonucleotide homopolymers. Binding to ei-
ther ssDNA or RNA is not inhibited by lactose [35].galectin-3 regulation. In fact, younger cells respond to
serum with a marked stimulation in galectin-3 expression The cell-cycle regulating properties of galectin-3 in-
clude the control of both cell replication and deathand an elevation in the levels of the nonphosphorylated
and phosphorylated protein, whereas older cells show through several possible mechanisms. The relation of
galectin-3 to cell proliferation is indicated by its up-regu-high basal levels and respond to serum with a reduced
protein and mRNA expression of galectin-3 [30]. lation and altered pattern of distribution and phosphory-
lation reported in 3T3 fibroblasts after mitogenic stimula-Galectin-3 is secreted from cells into the extracellular
space, although it lacks a signal sequence for transfer tion and before the onset of the S-phase of the cell cycle
[27–30]. Moreover, in the rat model of acute mesangialinto the endoplasmic reticulum and Golgi compartments
and entry into classical secretory pathways. In fact, it is proliferative glomerulonephritis induced by a single in-
jection of anti-Thy1.1 antibodies, galectin-3 has beenexternalized by a signal peptide and endoplasmic reticu-
lum-Golgi complex independent mechanism, which re- detected in the repopulating mesangial cell mass, thus
suggesting a role for this lectin in mesangial hypercellu-quires the N-terminal half of galectin-3 [31].
larity [36]. Direct evidence of the mitogenic potential
Galectin-3 mRNA splicing activity and cell-cycle of galectin-3 has been obtained in normal human lung
regulating function fibroblasts, with DNA synthesis and cell proliferation
being stimulated in a dose-dependent, lactose-inhibit-Intracellularly, galectin-3 acts as a pre-mRNA splicing
factor and also participates in the regulation of cell prolif- able manner requiring galectin-3 dimerization [37]. In
addition to regulating cell proliferation, galectin-3 favorseration and death.
The mRNA splicing activity of galectin-3 has been cell survival, as shown by the ability of this lectin to
protect against the cytotoxic effects of TGF-b in ratpostulated on the basis that most of this lectin is found in
the form of ribonuclease A–sensitive ribonucleoprotein mesangial cells grown in serum-free media [36]. A dual
control of cell cycle by galectin-3 has been shown in(RNP) complexes and that the N-terminal domain has
limited similarities with proteins of the heterogeneous human leukemia T cells or Jurkat cells. Galectin-3 is not
expressed in these cells under starvation, but is inducednuclear RNP complexes. In cell-free-splicing assays, nu-
clear extracts containing galectin-3 are capable of car- or up-regulated by factors capable of activating the cyclic
adenosine 39,59 monophosphate–responsive element bind-rying out pre-mRNA splicing activity, which is inhibited
by saccharides that bind galectin-3, but not by those that ing protein and nuclear factor-kB (NF-kB) transcrip-
tional pathways [38]. When transfected with galectin-3do not bind galectin-3 [32]. Splicing activity is reconstitu-
ted by addition of galectin-3 but not of other lectins with cDNA, cells grow more quickly under low serum condi-
tions and lower death rates in response to anti-Fas anti-either similar or different saccharide binding specificity
[32]. Nuclear extracts also contain galectin-1, which par- body or staurosporine compared with control transfec-
tants [38]. That galectin-3 in the cytosol associates withticipates in the mRNA splicing activity together with
galectin-3. In fact, depletion of both galectins from the Bcl-2, located on the outer membrane of mitochondria,
in a lactose-inhibitable manner through the CRD sug-nuclear extract results in a complete loss of splicing activ-
ity, whereas depletion of either galectin-1 or galectin-3 gests a direct participation of galectin-3 in cell death
suppression pathways [38]. Galectin-3 shares evolution-fails to abolish all of the splicing activity, and the residual
splicing activity remains saccharide inhibitable [33]. Ei- arily related sequence homologies with Bcl-2, involving
both the N- and C-terminal domains. The latter homol-ther galectin-1 or galectin-3 alone is sufficient to reconsti-
tute, at least partially, the splicing activity of nuclear ogy shows that galectin-3 contains the highly conserved
NWGR motif present in the BH1 domain of members ofextracts depleted of both galectins. The CRD of galectin-1
or galectin-3 is also sufficient to restore splicing activity the Bcl-2 family and that it participates in the galectin-3/
Bcl-2 association [39]. Galectin-1, which does not containto a galectin-depleted nuclear extract, though at a greater
concentration than the full-length polypeptide [33]. The an NWGR motif, induces apoptosis similarly to other
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Table 2. Galectin-3 ligands receptor and to induce mast cell (and basophil) activation
[52], thus suggesting a role for this molecule in allergy.Cell surface Extracellular environment
Eosinophils [53] and neutrophils [54] also bind IgEIgE receptor IgE
Carcinoembryonic antigen (CEA) Laminin through galectin-3, which therefore participates in their
Colon cancer mucin Tenascin IgE-dependent effector function. Binding of galectin-3 to
CD66 Fibronectin
neutrophils is mediated by the carcinoembryonic anti-Bacterial lipopolysaccharide Collagen IV
Lysosomal-membrane-associated gp90/Mac-2 binding protein gen-related glycoprotein CD66 [55], and it results in acti-
glycoproteins (LAMPs) 1 and 2 (M2 BP) vation of NADPH-oxidase [56] and superoxide produc-
Mac-1 AGEs
tion [57].Mac-3
Heavy chain of CD98 Other cell surface galectin-3 ligands are bacterial lipo-
L1 polysaccharide [58]; the lysosomal-membrane-associated
Myelin-associated glycoprotein
glycoproteins (LAMP) 1 and 2, adhesive glycoproteins
[59]; the Mac-1 antigen, corresponding to the a-subunit
(CD11b) of the CD11b/CD18 integrin; the Mac-3 antigen,
a macrophage differentiation antigen related immuno-members of the Bcl-2 family [38]. Galectin-3 also inhibits
chemically to LAMP-2 and the heavy chain of CD98, aapoptosis induced by the loss of cell anchorage (anoikis),
125 kD heterodimeric glycoprotein [60]; and the cellwith this inhibition involving cell cycle arrest at an an-
recognition molecules L1, the neural cell adhesion mole-oikis-insensitive point (late G1) through modulation of
cule, and the myelin-associated glycoprotein [61].gene expression and activities of cell cycle regulators
Other ECM proteins that are capable of binding to[40]. By virtue of its proproliferative [37, 38] and anti-
galectin-3 include tenascin [61], fibronectin, collagen IVapoptotic [38] action, galectin-3 is considered as an im-
[46], and gp90/Mac-2 binding protein (M2 BP). The lastmediate early gene possibly implicated in tumor growth,
is a multidomain and heavily glycosylated 90–97 kD pro-as shown by the abnormal expression of galectin-3 re-
tein showing homology with the cysteine-rich SRCR do-ported in several neoplasias [41–43].
main of the scavenger receptor in domain 1 [62]. It is
secreted by various cells and is present in normal serum
GALECTIN-3 ADHESIVE FUNCTION as well as in the ECM in the form of linear and ring-
As an adhesion molecule, galectin-3 regulates cell- shaped oligomers [63], which interact with galectin-3,
to-cell and cell-to-matrix interactions through its CRD fibronectin, collagen IV, collagen V, collagen VI (but
(Table 2). In the lectin-mediated cell adhesion, protein– not I and III), nidogen, and b1 (but not a2 and a6)
carbohydrate interaction is exploited, not just peptide integrin subunits [64].
motif recognition, with the sugar code significantly con- Interactions of galectin-3 with the ECM also include
tributing to the specificity of cellular selection of binding the cleavage of this lectin by two members of the matrix
partners by integrating with other recognition modes. metalloproteinase (MMP) family of enzymes, MMP-2
Cell surface galectin-3 molecules are capable of mediat- and MMP-9, and the inhibition of hydrolysis by tissue
ing homotypic cell adhesion by serving as a cross-linking inhibitor of metalloproteinase (TIMP)-2 [65]. The major
bridge between adjacent cells, bridging through attach- cleavage site is at the Ala62-Tyr63 bond contained in the
ment to a complementary serum glycoprotein(s), which N-terminal domain of galectin-3, with its hydrolysis gener-
is inhibited by lactose [44]. Moreover, galectin-3 (and ating an approximately 9 kD polypeptide comprising the
galectin-1) down-regulate cell adhesion to laminin through N-terminal end of the intact galectin-3 and a 22 kD frag-
its association with a1b1-integrin receptors in a lactose- ment with intact CRD [65]. However, formation of the
inhibitable manner, thus producing an anti-adhesive ef- 22 kD fragment alters the CRD so that it binds more
fect [45, 46]. However, under certain circumstances, ga- tightly to the glycoconjugates, thereby reducing self-
lectin-3 may promote cell adhesion to laminin, as is the association of the galectin molecules and abrogating the
case with neutrophils [47]. Alterations of tumor cell in- biologic properties dependent on such associations [66].
teraction with the basement membrane glycoprotein Finally, ECM turnover appears to be modulated by ga-
laminin are consistent features of the invasive and meta- lectin-3, given that its addition to primary cultures of rat
static phenotype. Qualitative and quantitative changes mesangial cells increases the synthesis of collagen IV
in the expression of cell surface laminin-binding proteins, and acts in synergy with TGF-b on matrix synthesis by
including a reduction of galectin-3, have been correlated producing a quantitatively similar stimulatory effect [36].
with the ability of cancer cells to cross basement mem-
branes during the metastatic cascade, and such pheno-
GALECTIN-3 AGE-RECEPTOR FUNCTIONtypic modifications have been shown to be associated
The AGE-receptor function of galectin-3 was sus-with tumor aggressiveness and poorer prognosis [48–51].
Galectin-3 has been shown to bind IgE and the IgE pected on the basis of the isolation of a sequence corre-
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sponding to galectin-3 by screening an expression library PKC substrate [70], was later shown to be phosphory-
lated by stimulation of cells with acidic or basic fibroblastfrom activated macrophages with anti-p90 antibody [17].
Among the members of the galectin family, galectin-3 growth factor (FGF), followed by its translocation on
the plasma membrane where it binds to the SH2 domain(and to a lesser extent, galectin-4) has been found to exhibit
high-affinity 125I-AGE-bovine serum albumin (BSA) bind- of adaptor protein, growth factor receptor-bound protein
2 (Grb2), in a complex with the guanine nucleotide re-ing with saturable kinetics. This binding is fully blocked
by excess unlabeled naturally formed AGE-BSA or syn- leasing factor Sos [71]. One study has been shown that
80K-H is involved in the signal transduction linking FGFthetic 2-(2-furoyl)-4(5)-furanyl-1H-imidazole (FFI)-BSA,
but it is not or weakly inhibited by either early intermedi- receptor 3 (FGFR3) to MAPK, with activated FGFR3
stimulating 80K-H phosphorylation and interacting withate glycation products or carbohydrate moieties specifi-
cally binding lectins, such as lactose. Scatchard plot anal- the phosphorylated protein in a complex with Grb2-Sos
and another protein p66 [72]. That 80K-H participatesysis is consistent with a single class of binding sites and
an affinity on the order of magnitude of the AGE-recep- in the activation of the p21(ras)-MAPK pathway sug-
gests that p90 can also participate in the signal transduc-tor and higher than that of carbohydrates, with binding
activity retained by the C-terminal domain and even tion triggered by RAGE [14].
However, the molecular mechanisms by which AGE-enhanced by removal of the N-terminal domain. In addi-
tion to p90, immunoprecipitation with anti-galectin-3 re- binding proteins associate and cooperate with each other
to specifically recognize the various AGE structures andveals galectin-3 as well as galectin-3-associated proteins
(40 and 50 kD) displaying AGE-binding activity. Galec- mediate their effects remain largely unknown. In fact,
inhibition of either p60 or p90 with blocking antibodiestin-3 interacting with AGEs assumes a distinct patchy
distribution on the cell surface, due to the formation has been shown to result in complete blockade of AGE-
induced up-regulation of ECM proteins and growth fac-of high-molecular weight complexes between galectin-3
and other membrane components, which seem to be tors in cultured mesangial cells [10, 11], suggesting that
both receptors are necessary in the modulation of dysreg-significant for displaying its AGE-receptor function [17].
The capacity of galectin-3 to bind to AGE, which was ulated tissue remodeling. Moreover, a predominant
involvement of galectin-3 in cell activation has recentlyfirst demonstrated in macrophages, has since been con-
firmed in other cell types. Galectin-3 from human astro- been questioned by our report that the galectin-3 knock-
out mouse develops accelerated glomerulopathy aftercytes has been shown to bind AGE-modified proteins,
with binding being blocked by the corresponding anti- induction of diabetes compared with the corresponding
wild type animal. In galectin-3 deficient mice, the morebody [67]. Likewise, galectin-3 expressed in human um-
bilical vein endothelial cells has been reported to bind pronounced proteinuria and mesangial expansion are
associated with more marked glomerular AGE accumu-labeled AGE-BSA, but FFI-BSA fails to compete with
AGE-BSA for binding, which differs from data in other lation compared with the galectin-3 expressing mice, de-
spite comparable degrees of metabolic derangement [ab-cells [68].
The lack of a transmembrane anchor sequence or sig- stract; Pugliese et al, Diabetologia 41(Suppl):A29, 1998].
These data suggest that galectin-3 deficiency may causenal peptide suggests that galectin-3 is associated with
other AGE-receptor components rather than playing an reduced removal of irreversibly glycated molecules, re-
sulting in enhanced AGE-mediated injury rather thanindependent role as an AGE-receptor. The macrophage
scavenger receptor could be one candidate, because of decreased AGE-induced cell activation. In sharp con-
trast, a lack of other AGE-independent galectin-3 actionsits homology with M2 BP [62], in addition to p90, which
was originally coisolated with p60 from liver membranes has not been found to contribute to the development of
glomerulopathy [abstract; Pugliese et al, Diabetologia[69]. At present, p60/AGE-R1, p90/AGE-R2 and galec-
tin-3/AGE-R3 are believed to act as a molecular complex 41(Suppl):A29, 1998].
(the so-called “AGE-receptor complex”), with the first
Galectin-3 expression in health and diseasebeing implicated mainly in AGE uptake and degradation
and the latter two being involved predominantly in cell Galectin-3 expression appears to be developmentally
regulated, being more abundant during embryogenesisactivation [15]. In fact, p90/AGE-R2 seems to have no
or weak AGE-binding activity, because binding of AGE- and development than in adult life. Both galectin-3 and
galectin-1 are first expressed in the trophectoderm cellsmodified proteins is inhibited by anti-80K-H antibodies
in U87MG glioblastoma cells [16], but not in human of the implanting embryo, thus suggesting a role for these
lectins in implantation. However, the lack of galectin-1astrocytes [67] and umbilical vein endothelial cells [68].
Conversely, it may be involved in signal transduction, as in galectin-1 null mutant mice and the lack of both galec-
tin-1 and galectin-3 in double mutant mice are compati-shown by its phosphorylation after exposure to AGE-
BSA, due to its sequence similarity with the 80K-H pro- ble with implantation [73].
During embryogenesis, galectin-3 and galectin-1 aretein [16]. This molecule, originally characterized as a
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differentially expressed in tissues, suggesting their partic- which is confined to the a-intercalated cell in the collect-
ing duct of a normal kidney, but it exhibits the apicalipation in the complex process of tissue differentiation
[74, 75]. In the first trimester, galectin-3 is expressed expression pattern typical of the mesonephric duct/ure-
teric bud lineage during embryogenesis in diseased epi-mainly in epithelia (skin, digestive and respiratory tracts,
and urothelium and excretory tubes of the kidney) but thelia of both multicystic dysplastic kidneys and autoso-
mal recessive polycystic kidneys [87]. Unlike tubules,also in myocardial cells, chondrocytes, notochord, and
liver, whereas galectin-1 is expressed in connective and neither glomeruli nor cultured mesangial cells express
galectin-3 [36, 88], which, however, becomes expressedderived tissues, such as smooth and striated muscle cells,
and in skin and gonadal epithelia [76]. However, the both in vivo and in vitro with increasing age of animals
and cells, respectively [88]. In young animals, galectin-3finding that animals homozygous for an allele carrying
a null mutation in the galectin-3 gene develop normally expression is induced during experimental glomerulone-
phritis by anti-Thy1.1 antibodies, with the lectin initiallyand are viable and fertile suggests that other proteins
compensate for the lack of galectin-3 [77]. detected in recruited macrophages and later in prolifer-
ating mesangial cells [36]. In liver, normal hepatocytesPostnatally, galectin-3 is detected in several tissues,
with its expression being altered either quantitatively or do not express the lectin, but it becomes detectable in
the cirrhotic liver as well as in hepatocellular carcinoma,qualitatively in various disease states.
Cells of the myeloid lineage, including monocyte-mac- independently of earlier hepatitis B virus infection [42].
In normal thyroid cells and in most benign thyroid le-rophages [60], neutrophils [54], eosinophils [53], and par-
ticularly basophils and mast cells [78], express galectin-3 sions, galectin-3 is not expressed, whereas it is detected
in thyroid malignancies of follicular and, less frequently,under normal conditions. As previously mentioned, ga-
lectin-3 is involved in the activation of these cells, with parafollicular cell origin, thus representing a marker for
preoperative identification of malignant thyrocytes onpathogenetic implications in diseases, such as allergy,
characterized by participation of bone-marrow-derived cytologic specimens obtained by fine-needle aspiration
biopsy [41].elements. Conversely, in B and T lymphocytes, galectin-3
is not expressed, although it is induced by infection of In the vessel wall, smooth muscle cells do not express
galectin-3, whereas endothelial cells show low but detect-T cell lines with human T-cell lymphotropic virus-I and
human immunodeficiency virus through the Tax and Tat able levels of this lectin. Interestingly, galectin-3 is in-
duced in proliferating vascular smooth muscle cells asgenes, respectively [79, 80], and in some types of lym-
phoma [81]. well as in cells (smooth muscle and foam cells in particu-
lar) from arteries of experimental animal models of ath-In bone, galectin-3 is expressed in cells of the osteo-
blastic and chondroblastic lineages during differentiation erogenesis and human patients with advanced athero-
sclerotic lesions [89, 90].and is up-regulated in hypertrophic conditions [82]. Con-
versely, it is down-regulated during osteoclast formation
Galectin-3 in diabetes and its relevance tofrom monocytes [83].
diabetic complicationsIn the nervous system, galectin-3 has been demon-
strated in certain neurons [84] and particularly in glial As already reported, galectin-3 is present in tissues
that are sites of long-term diabetic complications, includ-cells [67]. An up-regulated expression of galectin-3 has
been reported in primary astrocytomas and metastatic ing the nervous tissue, kidney, and vessels, although it
shows differential expression among the cell types com-tumors in the central nervous system [43]. Although in
astrocytomas, galectin-3 content decreases from low- to prising these tissues.
In the tissues of the nervous system, galectin-3 is ex-high-grade tumors, some tumor cell clones expressing
high amounts of galectin-3 emerge with increasing levels pressed in glial cells, with only a few neurons exhibiting
staining for this lectin, at variance with p60 and p90,of malignancy and tumor invasiveness [85].
Epithelia are major sites of galectin-3 expression, par- which are expressed in neural cells. In cultured human
astrocytes, the mRNA transcripts for AGE-R1, -R2,ticularly epidermal keratinocytes and epithelial cells of
the upper respiratory tract, gastrointestinal mucosa, uri- and -R3 do not appear to be regulated by AGEs, FFI,
or phorbol ester [67].nary tract, pancreatic ducts, breast, uterus, and prostate.
A reduced expression of galectin-3 has been observed Within the kidney, galectin-3 is expressed in a subset
of tubular epithelial cells but not in glomerular cells,in several carcinomas, including epidermal [48], breast
[49], and prostate [50]. Conflicting data have been re- although it becomes expressed at this level with increas-
ing age, both in vivo and in vitro. This age-related glo-ported regarding galectin-3 levels in colorectal cancer,
with either increased expression [86] or reduced (nu- merular/mesangial expression of galectin-3 is accelerated
and exacerbated by diabetes, in parallel with progressiveclear) content [51] during progression from normal mu-
cosa to adenoma to carcinoma and in liver metastasis. ECM accumulation, but in the absence of significant
proliferation. Tubular staining is also enhanced in diabe-The renal tubule epithelial cell also expresses galectin-3,
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tes [88]. In contrast with galectin-3, p90 is only slightly tissue. Up-regulation of galectin-3 may also favor expan-
sion of the cell compartment by stimulating cell growthup-regulated, whereas p60 is unchanged or reduced [ab-
stract; He et al, J Am Soc Nephrol 7:1871, 1996]. In and proliferation and macrophage activation [36] as well
as by producing an anti-apoptotic effect [38].cultured mesangial cells, galectin-3 expression is induced
by prolonged exposure to high glucose concentrations In conclusion, available data suggest that hyperglyce-
mia is associated with an up-regulation of galectin-3, anor on exposure to AGE-modified proteins [88].
In endothelial cells, components of the AGE-receptor AGE-binding protein and adhesive lectin, which might
influence development of diabetic complications by mod-complex are expressed under normal conditions and all
of them, particularly galectin-3, are subjected to up-regu- ulating the AGE-receptor-mediated effects and possibly
the tissue remodeling process.lation in response to AGE-modified molecules [68]. This
finding as well as the demonstration that galectin-3 is
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